Contents lists available at ScienceDirect



Cancer Treatment and Research Communications

journal homepage: www.elsevier.com/locate/ctarc



Breast cancer incidence and survival in elderly women during the 1989–2012 period: A population-based study in a French area



L. Schoutteten^{a,*}, M. Colonna^b, H. Curé^a, P. Delafosse^b, N. Mitha^c, N. Zerhouni^c, G. Gavazzi^c, A. Seigneurin^{b,d,e}

^a Medical Oncology Unit, Grenoble Alpes University Hospital, Cs 10217, 38043 Grenoble Cedex 9, France

^b Isère Cancer Registry, Grenoble Alpes University Hospital, Cs 10217, 38043 Grenoble Cedex 9, France

^c Gériatric Unit, Grenoble Alpes University Hospital, Cs 10217, 38043 Grenoble Cedex 9, France

^d Grenoble Alpes University, Techniques de l'Ingénierie Médicale et de la Complexité – Informatique Mathématiques et Applications Grenoble, UMR 5525,

38041 Grenoble, France

 $^{
m e}$ Medical evaluation Unit, Grenoble Alpes University Hospital, Cs 10217, 38043 Grenoble Cedex 9, France

ARTICLE INFO

Keywords: Breast cancer Incidence Overall survival Net survival Oncogeriatrics Cancer registry

ABSTRACT

Introduction: The incidence trend, characteristics and prognosis of breast cancer could differ by age group. The main objective was to describe the evolution of breast cancer incidence in women aged \geq 75 years and to estimate survival rates

Methods: A cohort study was set-up using data from a population-based cancer registry. Standardized incidence rates were computed during the 1989–2012 period. Ten-year net survival rates were estimated using cases diagnosed.

Results: A total of 3,523 breast cancers were diagnosed. The average annual increase of incidence rates was 7.9% (95% CI: 4.8–11.1%) and 1.1% (95% CI: 0.6–1.6%) for in situ and invasive breast cancers, respectively. Ten-year net survival rate was lower for women aged \geq 75 years (67% (95% CI: 61–74%)) compared to women aged 50–74 years (82% (95% CI: 81–83%).

Conclusion: A greater disease severity at the time of diagnosis, and less effective treatments given to elderly patients are the most plausible explanations for lower survival.

1. Introduction

Breast cancer is the most frequent of all cancer in women. In France, 48,763 news cases were diagnosed in 2012 [1], including 11,619 cases among women aged over 75 years. Breast cancer remains the leading cause of cancer death in France for women [2]. Incidence rates increases with age and the number of elderly people living after being diagnosed a breast cancer has increased due to longer life expectancy [3]. However, this age group remains underrepresented in clinical trials [4]. This age group is probably undertreated. The study of the incidence of breast cancer in elderly women would suggest a reflection on current screening strategies. The main objective of our study was to describe the evolution of breast cancer incidence during the 1989–2012 period in elderly women, i.e. women aged \geq 75 years, and between women aged \geq 75 years and women aged 50–74.

2. Material and method

2.1. Study design and setting

We analyzed the original data from an ongoing population-based cancer registry in Isère, a French administrative entity with nearly 1.2 million inhabitants.

2.2. Study population

The present study included all women aged \geq 50 years diagnosed with an incident primary in situ or invasive breast cancer between January 1, 1989 and December 31, 2012.

2.3. Data collection

The data were collected by the Cancer Registry of Isère. Sarcomas and lymphomas of the breast were excluded from this study. Stage at

* Corresponding author. E-mail address: lschoutteten@chu-grenoble.fr (L. Schoutteten).

http://dx.doi.org/10.1016/j.ctarc.2017.02.001

Received 29 August 2016; Received in revised form 14 January 2017; Accepted 6 February 2017 2468-2942/ © 2017 Published by Elsevier Ltd.

diagnosis was classified according to the Standards and guidelines for cancer registration in Europe published by the European Network of Cancer Registries and tumors not treated by surgery were considered as stage 4. An active search for the vital status at June 30, 2013 was carried out for all cases included in the study.

2.4. Statistical analysis

First, annual age-standardized incidence rates were computed for each calendar year from 1989 to 2012. A standardized incidence rate is the summary rate that would have been observed, given the agespecific rates observed in Isère, in a population with the age composition of some reference population, called the standard. The aim is to provide a single summary statistic that is independent of the effects of age. Age-standardized rates were computed by applying age-specific rates observed in Isère to the world standard population. We then applied the joinpoint regression model [5] to identify breakpoints in the trend of age-standardized incidence rates and to estimate average rates of change. Basically, the joinpoint model finds the best-fit line through several years of data using an algorithm that tests whether a multi-segmented line is a significantly better fit then a straight or lesssegmented line. The program starts with the minimum number of joinpoint (0 joinpoint, which is a straight line) and tests whether more joinpoints are statistically significant and must be added to the model.

Second, we restricted the description of the characteristics of breast cancers for cases diagnosed during the 2008–2012 period considering a higher proportion of missing values for these variables before 2008. A comparison of the characteristics among the 2 age groups was realized using a chi-square test.

Third, we conducted a survival analysis by computing overall and net survival rates for invasive breast cancers diagnosed during the 1989–2004 period considering a 10-year follow-up period and June 30th 2013 as the date of the end of follow-up. Overall survival rates were defined as the percentage of women who were alive 10 years after their diagnosis of cancer, whereas net survival rates referred to survival rates that would had been observed if breast cancer was the only possible cause of death. Overall survival was obtained from the Kaplan-Meier method [6]. Net survival was estimated using a method based on the assumption that mortality rates from other causes of death than breast cancer was approximated by mortality rates observed in the general population. Consequently, the cause of death was not necessary to estimate net survival. More precisely, net survival estimates were obtained from the Perm-Pohar method which included a correction for the bias related to informative censoring [7].

3. Results

3.1. Characteristics of the population

A total of 1,673 in situ and 13,660 invasive breast cancers were diagnosed during the 1989–2012 period among women aged over 50, including 139 in situ and 3,384 invasive breast cancers among women aged \geq 75 years. The characteristics of invasive cancers by age group are shown in Table 1. The data shown and their orders in Table 1 are those usually found in the histopathological report.

3.2. Incidence of breast cancer during the 1989-2012 period

The evolution of annual incidence rates during the 1989–2012 period is shown on Fig. 1. In 2012, the annual incidence rate of in situ and invasive cancers for women aged \geq 75 years were.

21.0 and 317.0 per 100,000, respectively. Among these women, the average annual increase by the incidence between 1989 and 2012 was 7.9% (95% CI: 4.8–11.1%) and 1.1% (95% CI: 0.6–1.6%) for in situ and invasive breast cancers, respectively. Incidence trends among women aged 50–74 were not similar. An average annual increase by

Table 1

Characteristics of invasive breast	cancers diagnosed	during the 2008-2012	period in the
Isère Department.			

	Age group at diagnosis				р
	50–74 years (n=2,629)		≥75 years (n=1,003)		
Mode of diagnosis Screen detected (mammography)	1,313	42.3%	66	6.3%	< 0.001
Histological type Ductal adenocarcinoma Lobular adenocarcinoma	2,048 413	77.9% 15.7%	706 157	70.4% 15.7%	< 0.001
Malignant tumour, unclassified	0	0.0%	30	3.0%	
Other types	168	6.4%	110	11.0%	
Oestrogen receptor status Positive Unknown	2,136 17	81.2% 0.7%	813 4	81.1% 0.4%	0.653
Progesterone receptor status Positive Unknown	1,652 17	62.8% 0.7%	621 4	61.9% 0.4%	0.565
Her-2 status Overexpression Unknown	267 214	10.2% 8.1%	77 170	7.7% 16.9%	< 0.001
SBR grade 1 2 3 Unknown Not tested	680 1,298 516 107 28	25.9% 49.4% 19.6% 4.1% 1.1%	224 491 174 107 7	22.3% 48.9% 17.4% 10.7% 0.7%	< 0.001
Stage at diagnosis 1 2 3 4 Unknown	1,390 685 152 177 225	52.9% 26.1% 5.8% 6.7% 8.6%	292 243 75 286 107	29.1% 24.2% 7.5% 28.5% 10.7%	< 0.001

7.0% (95% CI: 5.7–8.3%) was estimated during the 1989–2006 period for in situ cancers, followed by a non statistically significant decrease of incidence until 2012. For invasive cancers, a 1.5% (95% CI: 0.3–2.6%) annual decrease of incidence was estimated during the 2002–2012 period.

3.3. Survival

This analysis was based on women diagnosed with invasive breast cancers during the 1989-2004 period including 6,172 women aged 50–74 years and 1,893 women older than 75 years. 25% of women aged 50–74 died, and 1% were lost to follow-up. For women aged \geq 75 years, 67% died and 2% were lost to follow-up. Overall and net survival rates by age group are shown in Table 2. Overall survival rates at 10 years differed by age group at diagnosis, with 31% (95% CI: 29–33%) and 74% (95% CI: 73–76%) for women older than 75 years and aged 50–74 years, respectively (Table 3).

Among the 1,893 women aged \geq 75 years and diagnosed with an invasive cancer, 83.0% underwent surgery during the 1989–2004 period. Net survival rates for these women were 97% (95% CI-98%) at 1 year, 86% (95% CI: 82–89%) at 5 years and 78% (95% CI: 70–85%) at 10 years versus 81% (95% CI: 69–92%), 52% (95% CI: 31–74%) and 42% (95% CI: 12–71%) at 1, 5 and 10 years respectively, for women who did not undergo surgery.

Download English Version:

https://daneshyari.com/en/article/5697511

Download Persian Version:

https://daneshyari.com/article/5697511

Daneshyari.com